These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 14992909)
21. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery. Kim YS; Murkin JM; Adams SJ Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695 [TBL] [Abstract][Full Text] [Related]
22. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study. Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778 [TBL] [Abstract][Full Text] [Related]
23. A comparison between arterial- and venous-sampled activated clotting time measurements. Zisman E; Rozenberg B; Katz Y; Ziser A Isr J Med Sci; 1997 Dec; 33(12):786-8. PubMed ID: 9464347 [TBL] [Abstract][Full Text] [Related]
24. Comparison of ACT point-of-care measurements: repeatability and agreement. Bosch YP; Ganushchak YM; de Jong DS Perfusion; 2006 Jan; 21(1):27-31. PubMed ID: 16485696 [TBL] [Abstract][Full Text] [Related]
25. Interchangeability of activated clotting time values across different point-of-care systems. Thenappan T; Swamy R; Shah A; Nathan S; Nichols J; Bond L; Jolly N Am J Cardiol; 2012 May; 109(9):1379-82. PubMed ID: 22341924 [TBL] [Abstract][Full Text] [Related]
26. Heparin therapy during cardiopulmonary bypass in children requires ongoing quality control. Andrew M; MacIntyre B; MacMillan J; Williams WG; Gruenwald C; Johnston M; Burrows F; Wang E; Adams M Thromb Haemost; 1993 Dec; 70(6):937-41. PubMed ID: 8165615 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of a new point-of-care celite-activated clotting time analyzer in different clinical settings. The i-STAT celite-activated clotting time test. Paniccia R; Fedi S; Carbonetto F; Noferi D; Conti P; Bandinelli B; Giusti B; Evangelisti L; Pretelli P; Palmarini MF; Abbate R; Prisco D Anesthesiology; 2003 Jul; 99(1):54-9. PubMed ID: 12826842 [TBL] [Abstract][Full Text] [Related]
28. Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory. Doherty TM; Shavelle RM; French WJ Catheter Cardiovasc Interv; 2005 Jul; 65(3):330-7. PubMed ID: 15864806 [TBL] [Abstract][Full Text] [Related]
29. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Wendel HP; Heller W; Gallimore MJ; Bantel H; Müller-Beissenhirtz H; Hoffmeister HE Blood Coagul Fibrinolysis; 1993 Feb; 4(1):41-5. PubMed ID: 7681331 [TBL] [Abstract][Full Text] [Related]
30. Validation of a bedside activated clotting time test (Hemochron Jr II Signature) with low dose heparin therapy. Racioppi L; Quinart A; Biais M; Nouette-Gaulain K; Revel P; Sztark F Anaesthesia; 2009 Apr; 64(4):430-4. PubMed ID: 19317710 [TBL] [Abstract][Full Text] [Related]
31. Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron low range activated clotting time (ACT-LR). Tremey B; Szekely B; Schlumberger S; François D; Liu N; Sievert K; Fischler M Br J Anaesth; 2006 Oct; 97(4):453-9. PubMed ID: 16873382 [TBL] [Abstract][Full Text] [Related]
32. Clinical monitoring of activated clotting time during cardiothoracic surgery: comparing the Hemochron Hoffmann RF; Horsten S; Mariani MA; de Vries AJ Perfusion; 2023 Mar; 38(2):285-291. PubMed ID: 34596463 [TBL] [Abstract][Full Text] [Related]
33. Is the ACT two minutes after heparin injection reliable? Bellaiche AL; Nielsen PF; Kirkegaard H Perfusion; 2011 Jul; 26(4):322-6. PubMed ID: 21558299 [TBL] [Abstract][Full Text] [Related]
34. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330 [TBL] [Abstract][Full Text] [Related]
35. In vitro effects of aprotinin on activated clotting time measured with different activators. Wang JS; Lin CY; Hung WT; Thisted RA; Karp RB J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640 [TBL] [Abstract][Full Text] [Related]
37. Comparison of five point-of-care prothrombin and activated partial thromboplastin time devices based on age of blood sample. Searles B; Nasrallah F; Graham S; Lajara RB J Extra Corpor Technol; 2002 Sep; 34(3):178-81. PubMed ID: 12395962 [TBL] [Abstract][Full Text] [Related]
38. Changing systems for measuring activated clotting times: impact on the clinical practice of heparin anticoagulation during cardiac surgery. Patteril M; Stafford-Smith M; Toffaletti JG; Bute BP; Milano CA; Welsby IJ Clin Chim Acta; 2005 Jun; 356(1-2):218-24. PubMed ID: 15936321 [TBL] [Abstract][Full Text] [Related]
39. Clinical Evaluation of Measuring the ACT during Elective Cardiac Surgery with Two Different Devices. Falter F; Razzaq N; John M; Fassl J; Maurer M; Ewing S; Hofmeyr R J Extra Corpor Technol; 2018 Mar; 50(1):38-43. PubMed ID: 29559753 [TBL] [Abstract][Full Text] [Related]
40. Rapid quantitation of plasma heparin and antithrombin III levels for cardiopulmonary bypass monitoring, using fluorometric substrate assays. Savidge GF; Kesteven PJ; Al-Hasani SF; O'Brien PF Thromb Haemost; 1983 Oct; 50(3):745-8. PubMed ID: 6648894 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]